These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24630985)

  • 1. Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients.
    Tobin NP; Lindström LS; Carlson JW; Bjöhle J; Bergh J; Wennmalm K
    Mol Oncol; 2014 May; 8(3):741-52. PubMed ID: 24630985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.
    Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
    Clin Cancer Res; 2017 Dec; 23(24):7512-7520. PubMed ID: 28972043
    [No Abstract]   [Full Text] [Related]  

  • 3. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer.
    Niikura N; Iwamoto T; Masuda S; Kumaki N; Xiaoyan T; Shirane M; Mori K; Tsuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
    Cancer Sci; 2012 Aug; 103(8):1508-12. PubMed ID: 22537114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients.
    Bertucci F; Finetti P; Roche H; Le Doussal JM; Marisa L; Martin AL; Lacroix-Triki M; Blanc-Fournier C; Jacquemier J; Peyro-Saint-Paul H; Viens P; Sotiriou C; Birnbaum D; Penault-Llorca F
    Ann Oncol; 2013 Mar; 24(3):625-32. PubMed ID: 23117074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors for Luminal B-like Breast Cancer.
    Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
    Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
    Gluz O; Liedtke C; Huober J; Peyro-Saint-Paul H; Kates RE; Kreipe HH; Hartmann A; Pelz E; Erber R; Mohrmann S; Möbus V; Augustin D; Hoffmann G; Thomssen C; Jänicke F; Kiechle M; Wallwiener D; Kuhn W; Nitz U; Harbeck N
    Ann Oncol; 2016 Jun; 27(6):1035-1040. PubMed ID: 27022068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients.
    Zhao Y; Wang Y; Zhu F; Zhang J; Ma X; Zhang D
    Clin Exp Med; 2020 May; 20(2):249-259. PubMed ID: 31980982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters.
    Hashmi AA; Hashmi KA; Irfan M; Khan SM; Edhi MM; Ali JP; Hashmi SK; Asif H; Faridi N; Khan A
    BMC Res Notes; 2019 Sep; 12(1):605. PubMed ID: 31547858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.
    Koopman T; Buikema HJ; Hollema H; de Bock GH; van der Vegt B
    Breast Cancer Res Treat; 2018 May; 169(1):33-42. PubMed ID: 29349710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.
    Yuan JP; Wang LW; Qu AP; Chen JM; Xiang QM; Chen C; Sun SR; Pang DW; Liu J; Li Y
    PLoS One; 2015; 10(4):e0122734. PubMed ID: 25856425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial.
    Denkert C; Loibl S; Müller BM; Eidtmann H; Schmitt WD; Eiermann W; Gerber B; Tesch H; Hilfrich J; Huober J; Fehm T; Barinoff J; Jackisch C; Prinzler J; Rüdiger T; Erbstösser E; Blohmer JU; Budczies J; Mehta KM; von Minckwitz G
    Ann Oncol; 2013 Nov; 24(11):2786-93. PubMed ID: 23970015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
    Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
    J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl2 and Ki67 refine prognostication in luminal breast cancers.
    Chen LY; Tsang JY; Ni YB; Chan SK; Chan KF; Zhang S; Tse GM
    Breast Cancer Res Treat; 2015 Feb; 149(3):631-43. PubMed ID: 25648135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
    Iwamoto T; Katagiri T; Niikura N; Miyoshi Y; Kochi M; Nogami T; Shien T; Motoki T; Taira N; Omori M; Tokuda Y; Fujiwara T; Doihara H; Gyorffy B; Matsuoka J
    Oncotarget; 2017 Apr; 8(16):26122-26128. PubMed ID: 28412725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
    Wu J; Fang Y; Lin L; Fei X; Gao W; Zhu S; Zong Y; Chen X; Huang O; He J; Zhu L; Chen W; Li Y; Shen K
    Oncotarget; 2017 Jun; 8(24):38706-38716. PubMed ID: 28404972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.